HomeCompareFMTX vs GBDC

FMTX vs GBDC: Dividend Comparison 2026

FMTX yields 10.00% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.81M in total portfolio value
10 years
FMTX
FMTX
● Live price
10.00%
Share price
$20.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$38.7K
Annual income
$1,873.10
Full FMTX calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — FMTX vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFMTXGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FMTX + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FMTX pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FMTX
Annual income on $10K today (after 15% tax)
$849.58/yr
After 10yr DRIP, annual income (after tax)
$1,592.14/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,981,531.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FMTX + GBDC for your $10,000?

FMTX: 50%GBDC: 50%
100% GBDC50/50100% FMTX
Portfolio after 10yr
$10.44M
Annual income
$8,226,303.47/yr
Blended yield
78.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

FMTX
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$20.00
-0.0% upside vs current
Range: $20.00 — $20.00
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FMTX buys
0
GBDC buys
0
No recent congressional trades found for FMTX or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFMTXGBDC
Forward yield10.00%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$38.7K$20.85M
Annual income after 10y$1,873.10$16,450,733.83
Total dividends collected$14.3K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$20.00$14.00

Year-by-year: FMTX vs GBDC ($10,000, DRIP)

YearFMTX PortfolioFMTX Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$11,700$999.50$12,492$1,791.70$792.00GBDC
2$13,611$1,092.86$16,527$3,160.58$2.9KGBDC
3$15,752$1,188.27$23,588$5,904.90$7.8KGBDC
4$18,140$1,285.22$37,141$11,901.65$19.0KGBDC
5$20,793$1,383.22$66,205$26,463.38$45.4KGBDC
6$23,731$1,481.79$137,452$66,612.65$113.7KGBDC
7$26,972$1,580.48$342,372$195,298.53$315.4KGBDC
8$30,539$1,678.86$1,053,292$686,954.33$1.02MGBDC
9$34,453$1,776.52$4,111,439$2,984,416.95$4.08MGBDC
10$38,738$1,873.10$20,849,974$16,450,733.83$20.81MGBDC

FMTX vs GBDC: Complete Analysis 2026

FMTXStock

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.

Full FMTX Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this FMTX vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FMTX vs SCHDFMTX vs JEPIFMTX vs OFMTX vs KOFMTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.